Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,668 JPY | 0.00% | +0.45% | +12.55% |
04:33pm | BridgeBio Pharma Shares Decline After Q1 Financial Results | MT |
04-08 | U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.55% | 9.06B | A- | ||
+4.30% | 69.17B | A | ||
-12.75% | 4.96B | A- | ||
+42.38% | 4.47B | - | ||
+5.23% | 3.9B | B- | ||
+21.52% | 2.41B | B | ||
-19.05% | 2.41B | C- | ||
-28.72% | 2.23B | - | ||
+11.13% | 2.02B | - | - | |
+5.69% | 1.65B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4151 Stock
- Ratings Kyowa Kirin Co. Ltd.